Valuation dashboard for Boston Scientific Corporation (BSX) with P/E 17.79, P/B 2.44, EV/EBITDA 13.5 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular.
What would it be worth at its usual multiples?
Versus its usual multiples: cheap · Current P/E 17.8× · Multiples range: $72.43 · $72.43.
At its sector median (30.7×) $72 (+73 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
Analysis Summary
Boston Scientific Corporation reported revenue of $20.07B in the most recent fiscal year, growing at a 5-year CAGR of 15.2%.
Trailing-twelve-month margins: gross margin 70.4%, operating margin 21.0%, net margin 16.6%.
At $41.98 (closing price, October 30, 2026), BSX trades at a P/E of 17.79 and an ROE of 14.18%. Market capitalisation stands at $60.8B, placing it among large-cap names.
Balance sheet quality for BSX: debt-to-equity ratio of 0.51, current ratio of 1.24 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 17.79 |
| Price / Book | 2.44 |
| EV / EBITDA | 13.5 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BSX | Boston Scientific Corporation | $60.8B | 17.79 | 2.44 | 14.2% |
| MMSI | Merit Medical Systems, Inc. | $5.2B | 32.42 | 2.96 | 9.7% |
| LIVN | LivaNova PLC | $4.3B | 23.29 | 3.28 | 15.4% |
| ATRC | AtriCure, Inc. | $3.1B | 288.64 | 5.75 | 2.1% |
| MDT | Medtronic Plc | $123.5B | 23.78 | 2.46 | 10.6% |
| EW | Edwards Lifesciences Corporation | $53.0B | 52.88 | 4.99 | 9.7% |
| PEN | Penumbra, Inc. | $12.6B | 80.34 | 7.94 | 10.4% |
| TFX | Teleflex Incorporated | $5.9B | 2.10 | -31.8% |
Price
| Price | $41.98 (closing price, October 30, 2026) |
| Market Cap | $60.8B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 14.18% |
| Return on Invested Capital | 10.46% |
| Return on Assets | 7.72% |
| Gross Margin | 70.37% |
| Operating Margin | 21.05% |
| Net Margin | 16.56% |
Related companies: MMSI · LIVN · ATRC · MDT · EW · PEN · TFX
Explore sector: Healthcare · Medical - Devices
More sections of BSX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks